FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer’s Disease with Priority Review
Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If […]
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected […]
Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform
Provides update on COVID-19 therapeutic programsReports cash and cash equivalents of $97.5 million as of June 30, 2020GERMANTOWN, Md., Aug. […]
Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance
CINCINNATI, Aug. 07, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third […]
Applied Materials Introduces New Sym3® Etch System for Advanced Memory and Logic Chips
Sym3® Y tailored to critical conductor etch applications in 3D NAND, DRAM and foundry-logic nodesNewest offering broadens adoption of the […]
PFSweb Reports Record Second Quarter 2020 Results
ALLEN, Texas, Aug. 07, 2020 (GLOBE NEWSWIRE) — PFSweb, Inc. (NASDAQ: PFSW), a global commerce services company, is reporting results […]
Sprott Announces 2020 Second Quarter Results
TORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results […]
XORTX Appoints Dr. David Sans in New York as Director Corporate Development
CALGARY, Alberta, Aug. 07, 2020 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a […]
Greenlane Announces Second Quarter 2020 Financial Results
BOCA RATON, Fla., Aug. 07, 2020 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (“Greenlane” or “the Company”) (Nasdaq: GNLN), one of […]
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed […]
